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Introduction: To our knowledge, methylprednisolone pharmacokinetics and plasma
concentrations have not been comprehensively investigated in children with congenital
heart disease undergoing cardiac surgery with cardiopulmonary bypass. It is unknown
whether there is a significant influence of cardiopulmonary bypass on the plasma
concentrations of methylprednisolone and whether this may be an explanation
for the limited reported efficacy of steroid administration in cardiac surgery with
cardiopulmonary bypass.
Methods: The study was registered in the Dutch Trial Register (NTR3579; https://
www.trialregister.nl/trial/3428). Methylprednisolone 30 mg/kg was administered as an
intravenous bolus after induction of anesthesia. Methylprednisolone concentration was
measured with liquid chromatography tandem mass spectrometry and analyzed using
linear mixed-effects modeling.
Results: Thirty-nine patients were included in the study, of which three were excluded.
There was an acute decrease in observed methylprednisolone plasma concentration
on initiation of cardiopulmonary bypass (median = 26.8%, range = 13.9–48.14%,
p < 0.001). We found a lower intercept (p = 0.02), as well as a less steep slope
of the model predicted methylprednisolone concentration vs. time curve for neonates
(p = 0.048). A lower intercept (p = 0.01) and a less steep slope (p = 0.0024) if the
volume of cell saver blood processed was larger than 91 ml/kg were also found.
Discussion: We report similar methylprednisolone plasma concentrations as earlier
studies performed in children undergoing cardiopulmonary bypass, and we confirmed
the large interindividual variability in achieved methylprednisolone plasma concentrations
with weight-based methylprednisolone administration. A larger volume of distribution
and a lower clearance of methylprednisolone for neonates were suggested. The
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half-life of methylprednisolone in our study was calculated to be longer than 6 h for
neonates, 4.7 h for infants, 3.6 h for preschool children and 4.7 h for school children. The
possible influence of treatment of pulmonary hypertension with sildenafil and temperature
needs to be investigated further.
Keywords: methyprednisolone, pediatric, cardiopulmonary bypass, cardiac surgery, in vivo
INTRODUCTION
Every year, thousands of pediatric patients undergo cardiac
surgery facilitated by cardiopulmonary bypass (CPB). The use
of CPB has profound effects on distribution and elimination of
drugs due to hemodilution, changes in protein binding due to
the composition of the priming fluid, changes in oxygen delivery
to drug-eliminating organs, hypothermia, changes in acid–base
status, exclusion of the lungs from the circulation, and uptake of
drugs by CPB-circuit components (1–7).
CPB is known to initiate an intense systemic humoral and
cellular inflammatory reaction (8), which may lead to multiple
organ failure and prolonged stay at the intensive care unit (ICU)
(9). To attenuate this inflammatory response, corticosteroids are
often administered. There appears to be a limited influence of
corticosteroid administration on clinical outcomes in pediatric
cardiac surgery (10–12). It is unknown whether the inefficacy
of corticosteroid administration in cardiac surgery with CPB is
caused (partly) by the effects of CPB on the plasma concentration
of steroids.
Even though methylprednisolone (MP) is used often in
pediatric CPB patients, few studies are available concerning
its pharmacokinetics in pediatric patients (13). One study
is available on the effect of CPB on pharmacokinetic (PK)
parameters in adults (14). Studies in the adult population cannot
automatically be translated to the pediatric cardiac population
because of developmental and disease-specific differences in
pharmacokinetics and drug effect in children. The goal of the
current study was to describe total MP plasma concentrations
during CPB in pediatric patients after a single intravenous bolus
dose of 30 mg/kg at the induction of anesthesia.
METHODS
This study was performed at the Department of Cardiothoracic
Surgery and the Pediatric ICU of the Erasmus Medical Center,
Rotterdam, the Netherlands, and was part of a larger single-
center observational PK study in children during cardiac surgery
requiring CPB. The goal of the study is tomeasure concentrations
of drugs commonly used during pediatric cardiac surgery, with
the ultimate goal of performing population PKmodeling of these
drugs. The research protocol was approved by the institutional
Medical Ethical Review Board (MEC2011-400) and registered
in the Dutch Trial Register (NTR3579; https://www.trialregister.
nl/trial/3428). According to Dutch law, preoperative written
informed consent was obtained from the patient’s parents or legal
guardians and in children aged 12 to 18 years from the patient
as well.
Patients were included if they were younger than 18 years
and undergoing elective (congenital) cardiac surgery requiring
CPB. Exclusion criteria were no informed consent, no use of CPB
planned, and no MP received.
For every patient, we collected the following covariates: age
group (neonates 0–30 days of age, infants 30 days to 1 year of age,
preschool children 1–4 years of age, school children 4–12 years of
age), sex, weight, body surface area (BSA), preoperative treatment
with diuretics for volume overload (yes or no), preoperative
treatment with sildenafil for pulmonary hypertension (PHT; yes
or no), presence of cyanosis before and/or after surgery (yes or
no), and STSEACTS mortality risk category (15). We collected
the following CPB management covariates: use of a roller pump
vs. a centrifugal pump, oxygenator type used (Table 1), type of
arteriovenous tubing used (Table 1), volume of priming fluid, red
blood cells in the priming fluid (yes or no), fresh frozen plasma
in the priming fluid (yes or no), duration of CPB, duration of
aorta occlusion, use of a hemofilter (yes or no), and whether
there were multiple runs on CPB (yes or no). We collected
the following surgery-related covariates: minimum temperature
during CPB (normothermia >35◦C, mild hypothermia: 32–
35◦C, moderate hypothermia: 28–32◦C, severe hypothermia 20–
28◦C, deep hypothermia: <20◦C), blood loss during surgery,
diuresis during surgery, the volume of cell saver blood processed,
and the volume of cell saver blood returned to the patient.
Anesthesia
Anesthesia was induced with an inhalational (sevoflurane)
or intravenous (propofol and/or midazolam and sufentanil)
anesthetic technique. After placement of an intravenous cannula,
balanced anesthesia was performed with midazolam, sufentanil,
and pancuronium. After induction of anesthesia, patients
received MP–hemisuccinate (a prodrug of MP; Solumedrol,
Pfizer BV, Capelle a/d IJssel, NL) 30 mg/kg with a maximum dose
of 2 g as an intravenous bolus at the discretion of the attending
anesthesiologist. No preoperative dose of MP was given, and MP
was not added to the prime fluid. Anesthesia wasmaintained with
a midazolam continuous infusion and sufentanil as a continuous
infusion or as bolus doses at the discretion of the attending
anesthesiologist. In children older than 1 year, anesthesia was
alternatively maintained with a continuous infusion of propofol
and remifentanil.
CPB
The CPB systems used are described in Table 1. Priming fluid
contained fresh frozen plasma and Gelofusine R© (B. Braun
Medical BV, Melsungen, Germany). Red blood cells were added
to the priming to achieve a hematocrit of 28% during CPB.
The priming fluid was completed with 0.5 g/kg mannitol,









































TABLE 1 | CPB systems.
Oxygenator Reservoir Arterial filter Venous filter
cardiotomy
Defoaming sponge Silicone tubing PVC tubing Priming volume
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0.5 g/kg human albumin (Cealb R©, Sanquin, Amsterdam, the
Netherlands), 4.2 IU heparin per ml of priming volume (Leo
Pharma BV, Amsterdam, the Netherlands), and 2 to 5ml
sodium bicarbonate 8.4% (B. Braun Medical BV, Melsungen,
Germany). Anticoagulation was established with an initial bolus
of 300 IU/kg of porcine heparin with additional heparin
administered to maintain an activated clotting time higher than
480 s during the entire procedure. During CPB, non-pulsatile
blood flow was administered with flow rates between 1.8 and
3.2 L/min per m² BSA. Alpha-stat pH-management was used.
When deemed necessary, conventional ultrafiltration was applied
during CPB. According to the institutional protocol, no modified
ultrafiltration was used. The heart was arrested with antegrade
St. Thomas Hospital cardioplegic solution 10 to 15 ml/kg with
a temperature of 4◦C. In most procedures, mild hypothermia
(28–32◦C) was applied, with the exception of deep hypothermic
circulatory arrest (DHCA) procedures (18◦C) and beating-heart
procedures (36◦C).
All blood loss from the moment of skin incision to initiation
of CPB and from administration of protamine to skin closure
was salvaged together with the residual volume of the CPB
circuit in an Electa cell-saving device (Dideco, Sorin Group,
Modena, Italy).
Information on hemodynamics, mechanical ventilation,
administered medication, and perfusion data was recorded in
the automatic anesthesia registration system during the operation
and in PICIS (www.PICIS.com) in the ICU.
Blood Sampling for MP Analyses
Blood samples were taken in 2ml ethylenediaminetetraacetic acid
(EDTA) tubes (3.6mg EDTA, BD Vacutainer R©, BD Life Sciences,
Plymouth, UK) from the arterial line. Care was taken not to
exceed 5% of total circulating volume including the priming
volume of the CPB system. In case of arterial line dysfunction or
removal, sampling was stopped. Samples were taken at various
random timepoints during the operation at the discretion of
the attending anesthesiologist, with emphasis on the following
timepoints: after placement of the arterial line, before initiation
of CPB, just after reaching full flow on CPB, after reaching
the target temperature on CPB, and after weaning from CPB.
Samples were stored at 4◦C until processing. After centrifugation
(10min at 3,600 rpm), the supernatant serum was transferred
to polypropylene cryogenic vials with polypropylene screw caps
(Sarstedt Aktiengesellschaft and Co, Nümbrecht, Germany) and
stored at−80◦C until it was analyzed.
Assay Method
Drug concentrations were measured using liquid
chromatography tandem mass spectrometry (16). The method
for MP in human plasma was accurate (bias within −1.7 to
3.9%) and precise (within-run and between-run coefficients
of variation below 9.1% in all cases). The mean assay variance
of 51 samples evaluated for incurred samples reanalysis in
human plasma for MP was 4.8%. No sample value beyond±20%
deviation from the mean was observed.
Statistical Analysis
Differences between groups were calculated withMann–Whitney
U test for numeric data with a non-normal distribution, Fisher
exact test for binary categorical data, and χ2 test for nominal
or ordinal categorical data. Correlations were calculated with
Spearman correlations for data with a non-normal distribution
and Pearson correlations for data with a normal distribution.











To correct for the correlation of repeated measurements in
individual patients, MP plasma concentrations after initiation
of CPB were analyzed using linear mixed-effects modeling with
interindividual variability on intercepts and time slope (baseline
model). Based on individual MP concentration vs. time curves,
we assumed no changes in PK parameters after weaning from
CPB. Covariates were added individually as a fixed effect with
an interaction effect between time and the covariate in question,
because we expected a different time course for MP plasma
concentration after initiation of CPB for covariates. Model
assumptions were checked according to the protocol developed
by Zuur et al. (17) and were valid. Model fit was assessed
by Akaike Information Criterion and Bayesian Information
Criterion based on maximum likelihood.
We calculated which percentage of the decrease in MP plasma
concentration on initiation of CPB was caused by hemodilution
alone or metabolism alone. All calculations are based on a one-
compartment model for MP with first-order elimination (13).
The percentage decrease of MP plasma concentration on
initiation of CPB based on hemodilution alone was calculated:
Amount MP = C(0)∗CV
where amount MP is the amount of MP present in the central
compartment before initiation of CPB (mg), C (0) is the
concentration ofMP in the central compartment before initiation




where [MP] hemodilution is the calculated MP plasma
concentration after initiation of CPB based on hemodilution
alone (µg/ml), CV is patient circulating volume, and PV is
priming volume (ml).
% decrease MP hemodilution
=
(




where % decrease MP hemodilution is the % decrease in
MP plasma concentration on initiation of CPB based on
hemodilution alone.
The percentage decrease of MP plasma concentration on
initiation of CPB based on metabolism alone was calculated
as follows:
C (t) = C (0) ∗ 0.5
t
half−life
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All (n = 36) 7.2 (0.2–117.2) 7.8 (3–33.5) 40 (21–117) 22/14 12 20 2 2 (1–5)
Neonates (n = 5) 0.36 (0.2–0.5) 3.2 (3–3.6) 22 (21–23) 4/1 2 3 1 3 (2–4)
Infants (n = 17) 3.7 (1.3–11.2) 5.9 (3.4–9.7) 34 (23–47) 10/7 6 12 0 2 (1–5)
Preschool (n = 7) 28.4 (23.6–36.8) 10.7 (10–15) 51 (49–62) 5/2 4 4 1 2 (2–4)
School (n = 7) 57.6 (48.5–117.2) 17.7 (12.7–33.5) 74 (60–117) 3/4 0 1 0 2 (1–4)
BSA, body surface area; F, female; M, male.
where C (t) is MP plasma concentration in the central
compartment after the initiation of CPB (µg/ml), t is the amount
of time between the MP plasma measurements before and after
the initiation of CPB (min), and half-life is MP half-life and
equals 138min (3, 18).
% decrease [MP]metabolism =
(




Statistical analyses were performed using R (R Core Team;
A Language and Environment for Statistical Computing, R
Foundation for Statistical Computing, Vienna, Austria; 2019.
www.R-project.org), using the package lme4 (19).
RESULTS
In a 3.5-year period, 150 patients were included in the
larger single-center PK study. MP plasma concentrations were
measured in 39 patients. Three patients were excluded: two had
missing clinical data, and one received two doses of MP. This
left 36 patients for evaluation. A median of 7 (range = 6–10)
intraoperative blood samples were taken per patient (total 268
samples). Six patients also had 1 to 4 postoperative samples
taken (total 14 samples). Patient and surgery demographics are
described in Tables 2, 3.
Figure 1 shows the individual patient’s MP plasma
concentration vs. time plots based on the measured MP
plasma concentrations.
There were significant correlations for age group with
weight (Spearman ρ = 0.93, p < 0.001) and BSA (Spearman
ρ = 0.93, p < 0.001), oxygenator type (Spearman ρ = 0.84,
p < 0.001), AV-tubing type (Spearman ρ = 0.84, p < 0.001),
and volume of priming fluid (Spearman ρ = 0.58, p = 0.0002).
These correlations are given by the circumstance that we
use specific oxygenator types and AV-tubing types in specific
age groups.
In the CPB covariates, there were significant correlations
for volume of priming fluid and oxygenator type (Spearman
ρ = 0.83, p< 0.001), volume of priming fluid, and arteriovenous-
tubing type (Spearman ρ = 0.83, p < 0.001). These correlations
are given by the circumstance that specific oxygenators and
AV-tubing types have a specific need of priming volume and
thus priming type (addition of red blood cells to prevent
hemodilution) to prime the CPB system. Perfusion time and
aorta occlusion time were also correlated (Spearman ρ = 0.85,
p < 0.001).
In the surgery covariates, there was a significant correlation
for the volume of cell saver blood processed and blood loss
(Spearman ρ = 0.82, p < 0.001) and a weak but significant
correlation for the volume of cell saver blood returned (Spearman
ρ = 0.57, p= 0.003) (Figure 2).
Compared to other age groups, neonates had a
significantly larger volume of priming fluid as a percentage
of circulating volume (median = 88.5%, range = 82.7–133%
vs. median = 46.2%, range = 23.1–108.7%; p < 0.001)
and per kilogram of body weight (median = 80 ml/kg,
range = 74–120 ml/kg vs. median = 37 ml/kg, range = 19–
98 ml/kg; p < 0.001). They had a significantly longer
perfusion time (median = 216min, range = 185–280min
vs. median = 138min, range = 41–319min; p < 0.05) and
cross-clamp time (median = 134min, range = 104–177min
vs. median = 75min, range = 0–167min; p < 0.05). There
was more blood processed in the cell saver per kilogram of
body weight (median = 95 ml/kg, range = 60–337 ml/kg vs.
42 ml/kg, range = 11–220 ml/kg; p < 0.05), even though there
were no significant differences in blood loss, more cell saver
blood returned per kilogram of body weight (median = 38
ml/kg, range= 33–168 ml/kg vs. 16 ml/kg, range= 5–143 ml/kg;
p < 0.05), and a larger volume ultrafiltrated per kilogram of
body weight (median = 60 ml/kg, range = 21–99 ml/kg vs. 23
ml/kg, range = 0–68 ml/kg; p < 0.05). There were no significant
differences for any of the other covariates.
Children who had more cell saver blood processed were
younger (median = 39 days, range = 6–340 vs. 502 days,
range = 8–3,565 days, p < 0.05) and had corresponding
lower body weight (median = 3.4 kg, range = 3–9.7, vs.
10 kg, range = 3.6–33.5, p < 0.05) and BSA (median = 23,
range = 21–47 vs. 49, range = 23–117, p < 0.05). Perfusion
was more often performed with a centrifugal pump (44.4
vs. 7.4%, p = 0.024), and they had a higher incidence of
multiple perfusion runs (55.6 vs. 12%, p < 0.02). There was
a larger blood loss (median = 75 ml/kg, range = 10–259 vs.
median = 15.6 ml/kg, range = 1–63, p < 0.05), and more cell
saver blood returned (median = 64.9 ml/kg, range = 15.9–168.3
Frontiers in Cardiovascular Medicine | www.frontiersin.org 5 August 2021 | Volume 8 | Article 640543










































































































































































































































































































































































































































































































































































































































































































































































































vs. median= 14.5 ml/kg, range= 5–50 ml/kg, p< 0.05). Priming
volume as a percentage of circulating volume (median = 82.7%,
range = 45.4%−133% vs. median = 45.8%, range = 23.1–84%,
p < 0.05) and per kilogram of body weight (median = 74.4
ml/kg, range = 36–120 vs. 36.6 ml/kg, range = 19–76, p < 0.05)
was larger. Perfusion (median = 216min, range = 167–319 vs.
median = 116min, range = 41–231, p < 0.05) and cross-clamp
times (median= 107min, range= 56–177 vs. median= 75min,
range= 0–167, p< 0.05) were longer, andminimum temperature
(median = 30◦C, range = 19–34◦C vs. median = 32◦C,
range= 28–36◦C, p < 0.05) was lower. There were no significant
differences for any of the other covariates.
We compared the observed MP plasma concentration
immediately before and immediately after the initiation of
the first run of CPB when available (n = 29). The median
MP plasma concentration immediately before the initiation of
CPB was 10.6 µg/L (range = 5.3–23.3 µg/L). The median
MP plasma concentration immediately after the initiation of
CPB was 7.3 µg/L (range = 4.1–7.4 µg/L). There was a
significant, acute decrease in observed MP plasma concentration
with a median of 26.8% (n = 29, range = 13.9–48.14%,
p < 0.001) with a time difference between plasma concentration
measurements immediately before and after initiation of CPB of
13min (median, range = 7–36min). There was no significant
difference in decrease of MP plasma concentration on initiation
of CPB between age groups (neonates’ median MP plasma
concentration immediately before the initiation of CPB 7.1 µg/L
(range = 5.3–14.5 µg/L), median MP plasma concentration
immediately after the initiation of CPB 5.7 µg/L (range = 4.2–
7.7µg/L), median 22.0%, range= 18.2%−46.9%; infants’ median
MP plasma concentration immediately before the initiation of
CPB 11.9 µg/L (range = 7.1–23.3 µg/L), median MP plasma
concentration immediately after the initiation of CPB 9.0 µg/L
(range = 4.5–17.4 µg/L), median = 27.3%, range = 13.9–48.1%;
preschool median MP plasma concentration immediately before
the initiation of CPB 8.3 µg/L (range = 5.9–14.8 µg/L), median
MP plasma concentration immediately after the initiation of
CPB 6.1 µg/L (range = 4.1–10.2 µg/L), median = 27.2%,
range = 22.2–31.5%; school children’s median MP plasma
concentration immediately before the initiation of CPB 10.6
µg/L (range= 8.7–13.3µg/L), medianMP plasma concentration
immediately after the initiation of CPB 7.6 µg/L (range = 5.2–
11.2 µg/L), median = 28.0%, range = 14.0–45.6%; all p > 0.05).
There was no correlation between the percentage decrease in
observed MP plasma concentration on initiation of CPB and
the absolute volume of priming fluid [Spearman ρ = 0.042
(p = 0.83)], priming volume per kilogram of body weight
[Spearman ρ = −0.074 [p = 0.70)], or priming volume as
a percentage of the patient’s circulating volume (Spearman
ρ = −0.057, p = 0.78). Calculation of the expected percentage
decrease of MP plasma concentration on initiation of CPB based
on hemodilution alone was 31.6% (median, range= 18.8–57.1%),
and metabolism alone was 6.4% (median, range= 3.4–16.5%).
Mixed-Model Analyses
Compared to the baseline linear mixed-effects model, none
of the models with covariates included as a fixed effect with
Frontiers in Cardiovascular Medicine | www.frontiersin.org 6 August 2021 | Volume 8 | Article 640543
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an interaction with time showed an improvement in model
fit as represented by Akaike information criterion or Bayesian
information criterion.
Patient Covariates
We decided to use age group as a representative proxy variable
for weight and BSA, because there were significant correlations
between these covariates.
The model with age group added as a fixed effect with an
interaction with time showed a lower intercept (p = 0.02),
as well as a less steep slope for neonates (p = 0.048)
(Figures 3A,B).
Visual representation of the mixed-effects model with
preoperative PHT treated with sildenafil added as a fixed effect
with an interaction with time showed a non-significantly lower
intercept for patients with PHT, with a similar slope, albeit with
very large confidence intervals (Figure 4).
Addition of other patient covariates individually to the
baseline mixed-effects model showed no significant differences
in intercept or slope (Supplementary Figures 1–4).
CPB Covariates
We decided to not evaluate these covariates separately, but to
consider age group as a proxy variable for these factors. We
decided to evaluate perfusion time as a categorical variable
[perfusion time under 104min (25% quantile) vs. perfusion time
over 195min (75% quantile)]. Aorta occlusion time was not
evaluated separately, as there was a significant correlation with
perfusion time.
Addition of CPB covariates individually to the baseline
mixed-effects model as a fixed effect with an interaction with
time showed no significant differences in intercept or slope
(Supplementary Figures 5–11).
Surgery Covariates
We decided to use the volume of cell saver blood processed
as a proxy variable for both blood loss and cell saver blood
returned, as there were significant correlations between
these covariates. Cell saver blood processed was added
as a categorical covariate [cell saver blood processed <26
ml/kg (25% quantile), cell saver blood processed >91 ml/kg
(75% quantile)].
The model with the volume of cell saver blood processed
added as a fixed effect with an interaction with time showed a
lower intercept (p= 0.01), as well as a less steep slope (p= 0.0024)
if the volume of cell saver blood processed was larger than 91
ml/kg (Figures 5A,B).
Visual representation of the model with minimum
temperature during CPB added to the baseline model as a
fixed effect with an interaction with time showed a lower
intercept for patients with deep hypothermia, a less steep slope
for patients with deep hypothermia, and a steeper slope for
patients with normothermia, but with large confidence intervals
(Figure 6).
Addition of diuresis to the baseline model as a categorical
fixed effect [diuresis <4.7 ml/kg (25% quantile) vs. diuresis
>21 ml/kg (75% quantile)] with an interaction with time
showed no significant differences in intercept or slope
(Supplementary Figure 12).
DISCUSSION
To our knowledge, this is the first publication of MP for
congenital cardiac surgery incorporating data for children
younger than 4 years old.
Even though MP is used regularly in pediatric cardiac surgery
(20, 21), to our knowledge its pharmacokinetics and plasma
concentrations have not been comprehensively investigated
in children with congenital heart disease undergoing cardiac
surgery with CPB. It is unknown whether there is a significant
influence of CPB on the plasma concentrations of MP and
whether this influence may be an explanation for the limited
reported efficacy of steroid administration in cardiac surgery with
CPB (10–12).
A 26.8% decrease in observed MP plasma concentration
on initiation of CPB was shown in our study. For patients
with additional CPB runs during one surgical procedure, the
decrease in observed MP plasma concentration was shown
only for the first initiation of CPB, because the same CPB
system that was used on previous CPB runs was reused on
ensuing runs in the same patient. Initiation of CPB causes the
priming volume of the CPB system patient’s so it becomes to
be added to the patient’s central compartment to be added to
the central compartment, causing hemodilution. The observed
percentage decrease in concentration of MP on initiation of CPB
is smaller than what we would expect based on hemodilution
alone, and we could not show a correlation with the volume of
priming fluid. This smaller than expected decrease in observed
concentration may be due to redistribution of MP from the
child’s peripheral tissues back to the central compartment.
Unfortunately, no further information is available on the
redistribution half-time of MP in children. Alternatively, MP
may be formed from its prodrug MP hemisuccinate. The half-
time of MP hemisuccinate is 20 to 30min (13, 14). The amount
of time that passed between the time of MP hemisuccinate
administration to the time of measurement of the first MP
plasma concentration after the start of CPB was 70min (median,
range = 35–151min). Metabolism of MP hemisuccinate to
MP is thus a less likely candidate to explain the smaller
percentage decrease in concentration of MP on initiation of CPB,
as most of MP hemisuccinate will have been metabolized to
MP already.
Significant absorption of MP by plastic components of
the CPB system is highly unlikely, given that the observed
decrease in MP concentration on initiation of CPB is even
smaller than the calculated concentration decrease based on
hemodilution alone. This confirms the results of our previous
in vitro study, which showed MP recoveries close to 100% for
different CPB systems which were also used in the current
study (22).
The decrease in observed concentration on initiation of CPB
may in part be caused by metabolism of MP, as there is a
time difference between the MP concentration measured before
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FIGURE 1 | Individual MP concentration (mg/L) vs. time (min). Red vertical lines: time start cardiopulmonary bypass. Green vertical lines: time stop cardiopulmonary
bypass. T = 0: time of methylprednisolone dosing.
and after initiation of CPB of 13min (median, range = 7–
36min). The observed MP concentration difference in our study
was shown to be much larger than what can be explained by
metabolism alone.
Studies performed in neonates (23) and infants (24)
undergoing CPB and receiving an MP dose of 30 mg/kg
showed similar concentrations to our study in similar patient
groups. Thirty minutes after the initiation of CPB, neonates
achieved MP plasma concentrations of 4 vs. 4.4µg/ml (median,
range = 3.8–7.7µg/ml) in our study (23). Infants achieved MP
plasma concentrations of 7.2µg/ml 30min after the initiation
of CPB vs. 7.7µg/ml (median, range = 6.27–10.6µg/ml) in
our study, and 6.2µg/ml at protamine administration vs.
6.1µg/ml (median, range = 1.82–9.9µg/ml) in our study
(24). Our study confirms the large interindividual variability
in achieved MP plasma concentration with weight-based MP
administration (13, 25).
The lower MP concentration achieved with the same 30-
mg/kg dose in neonates that has been shown in our study was
previously shown in the studies performed by Keski et al. (23–
25). In ourmixed-effects model-based concentration–time curve,
we showed a significantly lower intercept for the MP plasma
concentration for neonates (Figures 3A,B), without significant
differences in the amount of time between administration of
MP and initiation of CPB compared to other age groups. The
lower estimated plasma concentration of MP at the beginning
of CPB originated from before the initiation of CPB. These
results suggest a larger volume of distribution (Vd) of MP
in neonates, as Vd is calculated by dividing the amount of
drug present in the body by administered dose. Developmental
differences in Vd between different age groups have been
described (4). Younger children have lower concentrations of
binding proteins, larger circulating volumes, and a smaller
percentage fat tissue.
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FIGURE 2 | Correlation plot of correlations between covariates calculated with Spearman correlations. AV, arteriovenous; BSA, body surface area; FFP, fresh frozen
plasma; PC, red blood cell concentrate; PHT, pulmonary hypertension; proc, processed; return, returned; SpO2 peripheral oxygen saturation; STSEACTSCat,
STSEACTS mortality risk category; Tmin, minimum temperature achieved during CPB.
Another covariate with a significantly lower intercept
for MP in the model-based concentration–time curve was
a large volume of cell saver blood processed during the
procedure (Figures 5A,B). There were significant differences
for various maturational covariates between groups with
different volumes of cell saver blood processed; thus, we
assume the lower intercept is based on an interaction with
age group.
Patients who were treated for PHT with sildenafil showed a
visual trend toward a lower intercept for MP in the model-based
concentration–time curve (Figure 4). The possible influence of
treatment of PHT with sildenafil on the Vd of MP thus needs to
be investigated in further studies.
In a one-compartment model, drug only leaves the
central compartment through elimination. The slope of the
concentration–time curve of a drug is thus a representation
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FIGURE 3 | (A) Predicted MP concentration (mg/L) vs. time (min) for all age groups after initiation of CPB based on the linear mixed-effects model. Gray ribbons: 95%
confidence interval. T = 0: start of CPB. (B) Predicted MP concentration (mg/L) vs. time (min) for all age groups after initiation of CPB based on the linear
mixed-effects model. Gray ribbon: 95% confidence intervals. T = 0: start of CPB.
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FIGURE 4 | Predicted MP concentration (mg/L) vs. time (min) for patients treated for pulmonary hypertension with sildenafil after initiation of CPB based on the linear
mixed-effects model. Gray ribbons: 95% confidence interval. T = 0: start of CPB.
of clearance (Cl). There was a significantly less steep slope of
the model-based MP concentration–time curve in neonates
compared to other age groups (p = 0.048), suggesting a lower
Cl of MP for neonates than for other children. If we were to
determine the half-life of MP based on the model-based MP
concentration–time curve for different age groups, it would
amount to longer than 6 h for neonates, 4.7 h for infants, 3.6 h for
preschool children, and 4.7 h for school children. Developmental
changes in Cl have been shown. Metabolism of cytochrome P450
(CYP) enzymes approaches approximately 50 to 70% of adult
levels at birth. By 2 to 3 years, CYP activity is larger than adult
values for selected isoenzymes, and by puberty, CYP activity
decreases to adult levels (26). A previous study in children aged
4 to 15 years receiving MP for an array of autoimmune diseases
showed large individual differences in Cl ranging from 0.18 to
0.93 L/kg per hour, with no correlation of Cl with age in the
previously mentioned study, although patients with Cl larger
than 0.5 L/kg per hour tended to be younger (13). We believe
the conflicting results from this study as opposed to ours lie in
the fact that the children in that study were older than those
in our study, with metabolism already largely at mature levels.
Comparison of the value of half-life for school aged children of
4.7 h in our study to the half-life of 2.5 h reported in a previous
pediatric study (13) suggests that there is a similar decrease in Cl
of MP in our study.
A large volume of cell saver blood processed was also
associated with a less steep slope of the model predicted
MP concentration vs. time curve (Figures 5A,B). We suspect
that this covariate is a proxy covariate for a large group
of other covariates, including patient characteristics and
surgery-related factors.
Our study does not rule out an effect of temperature
management on Cl. The MP plasma concentration vs. time
curve was almost horizontal for one patient treated with DHCA
and showed the steepest curve in one patient treated with
normothermic CPB. Both categories contained only one patient;
thus, it is pivotal that this covariate is investigated further in
larger studies.
To our surprise, there is no information on the
pharmacodynamics of MP with regard to the inflammatory
response caused by CPB. It is thus unknown which “therapeutic
levels” to aim for.
A randomized trial to determine the pharmacokinetics,
pharmacodynamics, safety, and efficacy in infants undergoing
heart surgery with CPB is, in our opinion, long overdue,
with and is fortunately currently recruiting 1,200 patients
(STRESS, https://clinicaltrials.gov/ct2/show/NCT03229538). In
this study, MP 30 mg/kg at the time of initiation of CPB
will be compared to placebo. The study will be completed
beginning of 2021. Thirty milligrams per kilogram is still
the most commonly administered dose of MP in pediatric
cardiac surgery; thus, we understand why this dose has been
chosen by the researchers. Comparable decreases in anti-
inflammatory mediator concentration and clinical outcomes
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FIGURE 5 | (A) Predicted MP concentration (mg/L) vs. time (min) for the volume of cell saver blood processed based on the linear mixed-effects model. Gray ribbon:
95% confidence interval. T = 0: start of CPB. (B) Predicted MP concentration (mg/L) vs. time (min) for the volume of cell saver blood processed based on the linear
mixed-effects model. Gray ribbon: 95% confidence interval. T = 0: start of CPB.
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FIGURE 6 | Predicted MP concentration (mg/L) vs. time (min) for temperature categories based on the linear mixed-effects model. Gray ribbon: 95% confidence
interval. T = 0: start of CPB.
have been reported with MP doses of 5 mg/kg or even 2 mg/kg,
however (25, 27).
LIMITATIONS
Our study has several limitations. First, the number of patients in
our study was relatively small.
We measured total plasma MP concentration and have no
information on albumin levels before, during, or after CPB in our
patients. Protein binding of MP is 78% (18), so a large change in
unbound plasma concentrations of MP is not expected.
As the study was part of a larger PK study with the aim
of performing population PK modeling for drugs commonly
used during pediatric cardiac surgery requiring CPB, blood
samples were taken at random timepoints. Usually, only a
limited number of observations can be obtained in pediatric
subjects; the population approach to obtain PK parameters is
the preferred approach. The population approach allows for the
analysis of sparse (limited number of observations per individual)
and unbalanced data (unequal distribution of observations in
various parts of the concentration–time profile in the individuals)
or a combination of both. As a result of this methodology,
when designing a pediatric study of which the data will be
analyzed using the population approach, it is advisable to collect
samples at different times (or time windows) in subgroups of
patients (28).
Last, there were significant differences between subgroups.
Since we performed an observational study, homogeneity of
groups was not intended in the study. Population PK modeling
has the goal of explaining interindividual differences.
CONCLUSION
We found a significant decrease in MP plasma concentrations
on initiation of CPB. Significant covariates of influence on the
MP plasma concentration vs. time curve after initiation were
age group (especially neonates) and large volume of cell saver
blood processed. As there is no further information regarding
pharmacodynamics of MP, we cannot currently recommend
increasing the dose for neonates. We recommend further
evaluation of the influence of treatment for PHT with sildenafil
and temperature management.
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